Can you provide the average price target for KORRO BIO INC stock?
16 analysts have analysed KRRO and the average price target is 19.53 USD. This implies a price increase of 84.55% is expected in the next year compared to the current price of 10.58.
NASDAQ:KRRO • US5009461089
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for KORRO BIO INC (KRRO).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-13 | Cantor Fitzgerald | Maintains | Overweight -> Overweight |
| 2026-03-13 | Raymond James | Upgrade | Market Perform -> Outperform |
| 2026-02-19 | Clear Street | Upgrade | Hold -> Buy |
| 2026-02-17 | William Blair | Upgrade | Market Perform -> Outperform |
| 2026-01-29 | Chardan Capital | Upgrade | Neutral -> Buy |
| 2026-01-29 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2026-01-29 | HC Wainwright & Co. | Upgrade | Neutral -> Buy |
| 2026-01-28 | Cantor Fitzgerald | Upgrade | Neutral -> Overweight |
| 2026-01-28 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2025-11-14 | Jones Trading | Downgrade | Buy -> Hold |
| 2025-11-13 | Chardan Capital | Downgrade | Buy -> Neutral |
| 2025-11-13 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2025-11-13 | William Blair | Downgrade | Outperform -> Market Perform |
| 2025-11-13 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2025-11-13 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-10-31 | Clear Street | Initiate | Buy |
| 2025-08-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-13 | Raymond James | Maintains | Strong Buy -> Strong Buy |
| 2025-08-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-07-24 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-13 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-13 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-04-29 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-04-16 | Chardan Capital | Initiate | Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.271M | 6.392M 181.46% | 1.795M -71.92% | 1.349M -24.85% | 3.55M 163.16% | 2.355M -33.66% | 34.406M 1,360.98% | 111.1M 222.91% | 259.58M 133.65% | 503.53M 93.98% | ||
| EBITDA YoY % growth | -80.904M -43.23% | -88.345M -9.20% | -83.062M 5.98% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -84.534M -43.28% | -91.91M -8.73% | -87.342M 4.97% | -77.708M 11.03% | -92.144M -18.58% | -107.712M -16.90% | -192.658M -78.86% | -232.731M -20.80% | -206.947M 11.08% | -96.876M 53.19% | 25.463M 126.28% | |
| Operating Margin | N/A | -4,047.12% | -1,366.43% | -4,329.11% | -6,830.52% | -3,034.14% | -8,180.79% | -676.42% | -186.27% | -37.32% | 5.06% | |
| EPS YoY % growth | -83.65 27.89% | -9.39 88.77% | -8.80 6.28% | -8.21 6.74% | -7.86 4.23% | -7.67 2.47% | -11.15 -45.48% | -13.71 -22.96% | -13.00 5.21% | -6.09 53.11% | 1.24 120.42% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -1.82 26.79% | -1.89 30.92% | -1.94 -1.01% | -2.03 -23.33% |
| Revenue Q2Q % growth | 492.997K -80.67% | 486.203K -66.70% | 486.203K -55.39% | 583.44K -54.84% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -20.041M 19.90% | -22.868M 15.93% | -24.077M -25.16% | -25.321M -59.42% |
All data in USD
16 analysts have analysed KRRO and the average price target is 19.53 USD. This implies a price increase of 84.55% is expected in the next year compared to the current price of 10.58.
KORRO BIO INC (KRRO) will report earnings on 2026-05-05.
The consensus EPS estimate for the next earnings of KORRO BIO INC (KRRO) is -1.82 USD and the consensus revenue estimate is 493.00K USD.
The number of analysts covering KORRO BIO INC (KRRO) is 16.